Thirty years.

 

Since the breakthrough of the patent system in the 1990s, China's innovative drug industry has, in the span of a single generation, covered ground that took others half a century – from generic manufacturing to generic-innovation hybrid, from following to running alongside, from "me-too" to "first-in-class," from sporadic out-licensing to hundred-billion-dollar deals.

 

Today, we can finally stand at the center of the world stage and declare: China's innovative drugs have risen!

 

But one question weighs on the entire industry: why are all the handshakes that seal deals still happening in the hotel corridors of San Francisco?

 

TONACEA 01: We Have the Strength, But We Lack a Home Ground

 

Data is cold, but it is also the most honest.

 

In 2025, the total value of out-licensing deals for Chinese innovative drugs exceeded US$135 billion. More than half of FDA-approved IND molecules globally originated from China. Among early-stage clinical project transactions worldwide, China accounted for 79%.

 

From ADCs to bispecifics, from CAR-T to oligonucleotides, from GLP-1 to radioligand therapies – Chinese scientists, Chinese entrepreneurs, and Chinese clinical researchers are leaving their mark on every hot track.

 

We are no longer the world's "followers." We are "runners alongside," and in some fields, even "leaders."

 

But every January, we still cross the Pacific, crowd into hotel lobbies in San Francisco, and meet clients, finalize deals, and seek capital in hallways. We compress a year's worth of collaboration into three days, pinning all our hopes on someone else's home ground.

 

What we lack is not capability.

 

What we lack is a premier home ground of our own that can link up with global decision-makers.

 

TONACEA 02: The Times Are Calling – China Needs Its Own JPM

 

The J.P. Morgan Healthcare Conference has been held for over four decades.

 

It has witnessed the ups and downs of global biopharma and defined where industry discourse resides – in the West, in San Francisco, under someone else's rules.

 

But today, the center of gravity of global innovation has shifted eastward.

 

China's clinical resources, patient population, research talent, capital dynamism, and policy environment are coalescing into a unique innovation ecosystem. We already possess the ability to define the rules, yet we still follow someone else's agenda.

 

This is neither fair nor sustainable.

 

The times are calling: China must have its own premier pharmaceutical industry summit.

 

Not to follow, not to benchmark, but to be rooted in the East, facing the globe, to build a new, high-frequency strategic hub open only to decision-makers.

 

TONACEA 03: TONACEA's "Great Power New Drugs" Conference Is the Answer

 

With over two decades of deep cultivation, TONACEA has witnessed the ups and downs and perseverance of countless Chinese new drug professionals.

 

We have hosted salons, organized forums, and traveled from city to city. We deeply understand that what China's innovative drugs need most is not a lively gathering, but an ecosystem platform that can truly drive transactions, link resources, and define the future.

 

That is why we created the "Great Power New Drugs" Global Conference.

 

This is not an ordinary conference.

 

This is the first time that Chinese innovative drugs, under the banner of "Great Power," are building their own home ground at the National Exhibition and Convention Center in Shanghai – China's window to the world and the permanent venue of the China International Import Expo.

 

A series of major milestones have already been announced.

 

Over 50 conference chairs represent the top brains of China's new drug industry; over 80 session curators are deep practitioners in their respective fields; over 60 thematic sessions cover XDC, CGT, oligonucleotides, CNS, GLP-1 – every track you care about has answers here; over 100 exhibitors, from multinational pharmaceutical companies to local leaders, have already reserved most of the available booths.

 

TONACEA 04: Truly Understanding "Why You Must Be There"

 

Many ask: Why should I fly to Shanghai? Isn't watching the livestream enough?

 

No.

 

Because some things cannot be delivered through a screen.

 

First, you will get information on-site that you cannot get online.

 

That unpublished clinical data chart shown by a speaker in a session? It won't be in the replay. That offhand comment by a CEO during a roundtable – "We're actually considering acquiring an XDC platform" – won't appear in a press release. The investor at the neighboring booth during a coffee break who tells you, "We just closed a fund focused on CGT" – that kind of information only flows on-site.

 

This is not "networking." This is intelligence.

 

Second, you will meet people on-site that you cannot meet online.

 

That BD head at a large pharma company you've been tracking for six months – normally impossible to schedule a meeting with, and emails go unanswered. But on July 22, they will be standing in the back of a session. The technology platform you've been searching for two years? Its founder is at the neighboring booth. The investor you've always wanted to meet? They will be sitting right next to you at the private dinner.

 

This is not "luck." This is density.

 

Third, you will see trends on-site that you cannot see clearly online.

 

More than 60 thematic sessions are not isolated. When you piece together the core insights from sessions on XDC, CGT, oligonucleotides, CNS, GLP-1, and more, a complete picture emerges: where capital is flowing, what MNCs are acquiring, where the next hotspot will be.

 

This is not "information." This is judgment.

 

Fourth, you will close deals on-site that you cannot close online.

 

In the meeting pods, the documents signed are not letters of intent – they are term sheets. In the closed-door sessions, what is exchanged is not business cards – it is pipeline data. At the dinners, what is clinked is not wine glasses – it is valuations.

 

 

Every one of the US$135 billion in BD deals was finalized at a moment of "person-to-person" connection. You can make connections online, but you cannot build trust online.

 

This is not a "conference." This is a battlefield.

 

TONACEA 05: It's Time – The Assembly Call Has Sounded

 

The countdown has begun – less than two months to go.

 

Over 50 conference chairs and over 80 session curators are taking their positions. More than 60 thematic sessions are being finalized. Most of the booths representing over 100 exhibitors have already been reserved. Overseas securities firms, law firms, and think tanks are continuing to join.

 

This is not a conference.

 

This is the first collective gathering of China's innovative drugs, on their own soil, issuing a call to the world.

 

July 22, National Exhibition and Convention Center (Shanghai). Decision-makers only – onlookers need not apply.

 

If you are a founder, here you will find the capital and partners you need. If you are a BD head, here you will find the molecules and projects you need. If you are an investor, here you will find the tracks and teams you need.

 

China's innovative drugs have suffered from the lack of a home ground for too long. Now, we are building it ourselves.

 

It's time.

 

July 22-24, CPIC 2026 – The Inaugural "Great Power New Drugs" Global Conference will be grandly held.

 

Early bird tickets are available for a limited time. Secure yours now.

 

See you on-site.